8.1.5: Other Antineoplastic Drugs

Part of chapter 8 Malignant Disease & Immunosuppression, section 8.1 Cytotoxic Drugs

High-level prescribing trends for Other Antineoplastic Drugs (BNF section 8.1.5) across all GP practices in NHS England for the last five years. You can explore prescribing trends for this section by CCG, or learn more about this site.

No prescriptions found.

Do you need help with your analysis? We can often provide one-off custom extracts from our prescribing data for free. to find out more.

Chemicals

Abemaciclib (0801050CL)
Afatinib (0801050BP)
Axitinib (0801050BJ)
Bexarotene (0801050AB)
Binimetinib (0801050CN)
Carboplatin (0801050F0)
Celecoxib (0801050AY)
Dasatinib (0801050AN)
Docetaxel (0801050D0)
Encorafenib (0801050CM)
Erlotinib (0801050AE)
Everolimus (0801050AX)
Gefitinib (0801050AW)
Hydroxycarbamide (0801050P0)
Ibrutinib (0801050BS)
Imatinib Mesilate (0801050AA)
Lapatinib (0801050AT)
Mitotane (0801050R0)
Nilotinib (0801050AS)
Nintedanib (0801050BT)
Olaparib (0801050BY)
Osimertinib (0801050CG)
Paclitaxel (0801050V0)
Palbociclib (0801050CB)
Pazopanib (0801050AZ)
Pipobroman (0801050BH)
Ponatinib (0801050BQ)
Procarbazine Hydrochloride (0801050U0)
Ruxolitinib (0801050BI)
Sorafenib (0801050AJ)
Sunitinib (0801050AM)
Temozolomide (0801050Y0)
Topotecan (0801050AF)
Trametinib (0801050CH)
Trastuzumab (0801050AD)
Tretinoin (0801050X0)
Vandetanib (0801050BG)